Pioglitazone

Pioglitazone

Pioglitazone Recall

Get an alert when a recall is issued.

Questions & Answers

Side Effects & Adverse Reactions

There is currently no warning information available for this product. We apologize for any inconvenience.

Legal Issues

There is currently no legal information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

Monotherapy and Combination Therapy

Pioglitazone tablets USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings [see Clinical Studies (14)].

Important Limitations of Use

Pioglitazone tablets USP exert their antihyperglycemic effect only in the presence of endogenous insulin. Pioglitazone tablets USP should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings.

Use caution in patients with liver disease [see Warnings and Precautions (5.3)].

History

There is currently no drug history available for this drug.

Other Information

Pioglitazone hydrochloride tablets USP are a thiazolidinedione and an agonist for peroxisome proliferator-activated receptor (PPAR) gamma that contains an oral antidiabetic medication: pioglitazone.

Pioglitazone [(±)-5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-] thiazolidinedione monohydrochloride contains one asymmetric carbon, and the compound is synthesized and used as the racemic mixture. The two enantiomers of pioglitazone interconvert in vivo. No differences were found in the pharmacologic activity between the two enantiomers. The structural formula is as shown:

Chemical structure

C19H20N2O3S•HCl M.W. 392.90

Pioglitazone hydrochloride, USP is an odorless white crystalline powder. It is soluble in N,N-dimethylformamide, slightly soluble in anhydrous ethanol, very slightly soluble in acetone and acetonitrile, practically insoluble in water, and insoluble in ether.

Pioglitazone tablets USP are available for oral administration containing 15 mg, 30 mg, or 45 mg of pioglitazone (as the base) formulated with the following excipients: carboxymethylcellulose calcium, hydroxypropyl cellulose, magnesium stearate, and mannitol.

Pioglitazone Manufacturers


  • International Labs, Inc.
    Pioglitazone Tablet [International Labs, Inc.]
  • Teva Pharmaceuticals Usa Inc
    Pioglitazone Tablet [Teva Pharmaceuticals Usa Inc]
  • Mylan Institutional Inc.
    Pioglitazone Tablet [Mylan Institutional Inc.]
  • Teva Pharmaceuticals Usa Inc
    Pioglitazone Tablet [Teva Pharmaceuticals Usa Inc]
  • Ranbaxy Pharmaceuticals Inc.
    Pioglitazone Tablet [Ranbaxy Pharmaceuticals Inc.]
  • Ranbaxy Pharmaceuticals Inc
    Pioglitazone Tablet [Ranbaxy Pharmaceuticals Inc]
  • Medvantx, Inc.
    Pioglitazone Tablet [Medvantx, Inc.]
  • Clinical Solutions Wholesale
    Pioglitazone Tablet [Clinical Solutions Wholesale]
  • Mylan Pharmaceuticals Inc.
    Pioglitazone Tablet [Mylan Pharmaceuticals Inc.]
  • International Labs, Inc.
    Pioglitazone Tablet [International Labs, Inc.]
  • American Health Packaging
    Pioglitazone Tablet [American Health Packaging]
  • Macleods Pharmaceuticals Limited
    Pioglitazone Tablet [Macleods Pharmaceuticals Limited]
  • Sandoz Inc
    Pioglitazone Tablet [Sandoz Inc]
  • Carilion Materials Management
    Pioglitazone Tablet [Carilion Materials Management]
  • Carilion Materials Management
    Pioglitazone Tablet [Carilion Materials Management]

Login To Your Free Account